sIII

Question 1

ch EBRT vs ch in NCDB 13270 sIII-IV EAC pts study from Stanford:
benefit of EBRT in univariable analysis?

Answer 1

EBRT: 5 - 9 % / absolute 5y survival in t.1 and t.2 EAC respectively

Question 2

ch EBRT vs ch in NCDB 13270 sIII-IV EAC pts study: benefit of EBRT in multivariate analysis?

Answer 2

EBRT benefit:
IIIC t.1 (*IIIC2) HR 0.73, p=0.01

IIIB & IIIC for t.2 HR 0.79, p<0.0001

No benefit for IIIA regardless of histology

Question 3

Risk factors for 🔄 s.III EAC as per MSKCC?

Answer 3

g3 or t.2 ca HR 4.2: 54 vs. 19% 🔄 at 5y

+ cytology HR 2.9 61vs.29% at 5y

deep myometrial invasion HR 2.3 36vs26% at 5y

Question 4

Chances for 🔄 s.III EAC as per MSKCC ~ # of risk factors?

Answer 4

5y relapse rate- risk of death
0: 13-11%

1: 27-20%
2: 62-56%

Question 5

Japanese RCT of Tax-Platinum vs Doxorubicin-Cis: 788🧘‍♀️; 2006-2011; discontinuation rate b/c side effects?

Answer 5

7% Doxorubicin Cis

6% Docetaxel Cis

12% Carbo Tax

Question 6

Japanese RCT of Tax-Platinum vs Doxorubicin-Cis: 788🧘‍♀️; high risk s.I-II, III, IV; <2 cm residual; 2006-2011; median f/u 7y: PFS and OS?

Answer 6

No 🔼

5y PFS: 73-79%
5y OS: 82-88%

Question 7

Japanese RCT of Tax-Platinum vs Doxorubicin-Cis: 788🧘‍♀️; high risk s.I-II, III, IV; <2 cm residual; 2006-2011; Dose limiting toxicity of regimens?

Answer 7

Docetaxel - Cisplatin: best tolerated:
> GI toxicity; not much hematologic;

Docetaxel-Carbo: neutropenia
Paclitaxel-Carbo: neurotoxicity